Insider Selling: Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells $1,988,880.72 in Stock

Posted by Geri Gentry on Oct 24th, 2026

Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 75,508 shares of the firm’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $26.34, for a total value of $1,988,880.72. Following the transaction, the insider owned 180,808 shares of the company’s stock, valued at $4,762,482.72. The trade was a 29.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total transaction of $3,924,676.63.
On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total value of $6,329,182.65.
On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.02, for a total transaction of $3,674.72.
On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.73, for a total transaction of $4,812,181.01.

Alamar Biosciences Stock Performance

ALMR stock opened at $30.69 on Friday. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $2.13 billion and a price-to-earnings ratio of -15.66. The firm’s 50-day moving average price is $30.74. Alamar Biosciences, Inc. has a one year low of $18.84 and a one year high of $39.61.

Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14. The company had revenue of $29.43 million during the quarter. As a group, equities analysts predict that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Stifel Nicolaus boosted their price objective on Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings raised shares of Alamar Biosciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. lifted their target price on Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Alamar Biosciences in a research report on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.80.

View Our Latest Analysis on Alamar Biosciences

Hedge Funds Weigh In On Alamar Biosciences

Hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new stake in shares of Alamar Biosciences in the second quarter worth $283,000. State Street Corp acquired a new position in Alamar Biosciences during the 2nd quarter valued at $3,930,000. Wellington Management Group LLP acquired a new stake in Alamar Biosciences during the second quarter worth about $12,407,000. Finally, Braidwell LP acquired a new position in Alamar Biosciences in the 2nd quarter valued at approximately $29,365,000.

Alamar Biosciences Company Profile

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.